CCND1 and breast cancer: In agreement, our results indicated that MET increased the level of p‐APMK in drug‐resistant and drug‐sensitive breast cancer cells, and also reduced the levels of other proteins associated with cell proliferation (cyclin D1 and PCNA; Figure 1F).